Chad Hummel, MD
Ophthalmology · Largo, FLNPI 1770877284
Payments from drug & device makers
Across 295 payments — averaging $60.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$6K
- Glaukos Corporation$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- AbbVie$2K
- Alcon$1K
- Lensar, Inc.$1K
- plus $5K from 23 others
What the payments were for
- Consulting fees$4,95028%
- Speaking & faculty fees$1,0006%
- Food & beverage$12,02967%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 19 | $6,053 |
| Glaukos Corporation | 17 | $1,756 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $1,597 |
| AbbVie(2 entities) | 69 | $1,595 |
| Alcon | 29 | $1,121 |
| Lensar, Inc. | 10 | $1,056 |
| NEW World Medical,inc. | 10 | $837 |
| Mallinckrodt Hospital Products Inc. | 13 | $699 |
| Johnson & Johnson Surgical Vision, Inc. | 29 | $685 |
| Novartis | 10 | $518 |
| Sight Sciences, Inc. | 13 | $470 |
| Carl Zeiss Meditec USA, Inc. | 2 | $227 |
| Eyevance Pharmaceuticals LLC | 6 | $223 |
| Kala Pharmaceuticals, Inc. | 10 | $180 |
| Aerie Pharmaceuticals, Inc. | 3 | $157 |
| Ocular Therapeutix, Inc. | 2 | $136 |
| Dompe US, Inc. | 3 | $108 |
| Rxsight Inc | 3 | $92 |
| Tarsus Pharmaceuticals, Inc. | 3 | $76 |
| Nova Eye, Inc. | 1 | $72 |
| Sun Pharmaceutical Industries Inc. | 3 | $55 |
| Genentech USA, Inc. | 2 | $54 |
| Oyster Point Pharma, Inc. | 2 | $51 |
| Biotissue Holdings Inc. | 2 | $43 |
| Rayner Intraocular Lenses Limited | 1 | $29 |
| Eyepoint US, Inc. | 2 | $27 |
| Amgen | 1 | $23 |
| Beaver-visitec International, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$5,726
- STELLARIS ELITE$5,053
- Crystalens Accommodating IOL (AT-52AO)$5,053
- Trulign IOL$5,053
- Akreos AO IOL$5,053
- LENSAR LASER SYSTEM$797
- ACTHAR$499
- Ahmed Glaucoma Valve$455
- Kahook Dual Blade$455
- Clareon$421
- DURYSTA$368
- ENVISTA$365
- Tecnis IOL$244
- STELLARIS$224
- Clearpath$211
- Streamline$211
- Hydrus Microstent$147
- OMNI(R) SURGICAL SYSTEM (US)$136
- SION SURGICAL INSTRUMENT$136
- Flarex$134
How this compares
$17,979 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 82 | $108,194 |
| LumiganBimatoprost | 86 | $57,993 |
| XiidraLifitegrast | 26 | $25,996 |
| MieboPerfluorohexyloctane/Pf | 18 | $16,814 |
| ProlensaBromfenac Sodium | 35 | $12,774 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $11,238 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $11,089 |
| Loteprednol Etabonate | 30 | $5,551 |
| Prednisolone Acetate | 96 | $5,161 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $5,082 |
| Latanoprost | 230 | $3,331 |
| ValacyclovirValacyclovir Hcl | 15 | $1,459 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 86 | $1,288 |
| Timolol Maleate | 87 | $1,108 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 16 | $1,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,595 | $177,275191 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $6,053 | $42,81044 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $1,597 | $18,32565 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $157 | $11,23818 claims |
| AlconSimbrinza | $1,121 | $5,08218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Largo
- Philip ShettleLargo$1.6M
- Neel DesaiLargo$1M
- Robert WeinstockLargo$855K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.